Study flow diagram (IMAGE)

Sichuan International Medical Exchange and Promotion Association

Study flow diagram

Caption

A total of 62 patients were initially screened across five study centers for eligibility in this study. Of these, 15 patients were excluded due to various reasons: 10 failed the screening, 3 declined participation, 1 was ineligible due to anemia, and 1 was excluded for other reasons. Ultimately, 46 patients met the eligibility criteria and were enrolled to receive the combination treatment of pyrotinib (400 mg orally once daily) and fulvestrant (500 mg intramuscularly, per protocol). These patients were subsequently followed to assess the efficacy and safety of the treatment regimen.

Credit

Ying Wang

Usage Restrictions

Please cite source

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.